Kornimate/medical-research-clean huggingface dataset:
a randomized, double-blinded, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma

Conditions: Carcinoma, Hepatocellular

Summary: the purpose of the study is * find out if patients receiving sorafenib will live longer * find out if sorafenib has any effect on patient reported outcomes * find out if sorafenib prevents the growth or shrinks liver tumors and / or their metastases * determine the pharmacokinetics (pk) in patients with liver cancer


Eligibility criteria:
inclusion criteria: * ages eligible for study: 18 years and above, genders eligible for study: both * patients who have a life expectancy of at least 12 weeks * patients with advanced hepatocellular carcinoma (hcc) (unresectable, and/or metastatic) which has been histologically or cytologically documented * patients must have at least one tumor lesion that meets both of the following criteria 1. accurately measured in at least one dimension according to response evaluation criteria in solid tumors (recist) 2. not been previously treated with local therapy * patients who have received local therapy, such as surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation are eligible. previously treated lesions will not be selected as target lesions. local therapy must be completed at least 4 weeks prior to the baseline scan * patients who have an eastern co-operative oncology group (ecog) performance status of 0, 1, or 2 exclusion criteria: * previous or concurrent cancer that is distinct in primary site or histology from hcc, except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (ta \[noninvasive papillary carcinoma\], tis \[carcinoma in situ: "flat tumor"\]\&t1 \[tumor invades subepithelial connective tissue\]). any cancer curatively treated \> 3 years prior to entry is permitted * history of cardiac disease * active clinically serious infections * known history of human immunodeficiency virus (hiv) infection * known central nervous system (cns) tumors including metastatic brain disease * patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry
heated chemotherapy for cancers that have spread to the chest cavity

Conditions: Pleural Metastases; Breast Cancer; Colon Cancer; Ovarian Cancer; Uterine Cancer; Renal Cell Cancer; Thymic Cancer

Summary: cancers that have spread to the inner lining of the chest are classified as stage iv and bear a poor prognosis. surgery is rarely an option, with palliative chemotherapy and/or radiation therapy the only treatment options. this study intends to evaluate whether surgical removal of all visible tumor on the chest wall followed by bathing the chest cavity in heated chemotherapy solution will improve outcomes for these advanced cancers.


Eligibility criteria:
inclusion criteria: 1. adults aged 18-75 years 2. radiographic evidence of pleural dissemination with histologically or cytologically confirmed diagnosis. 3. primary source control (breast, ovarian, uterine, colon, renal cell, thymic cancer) 4. adequate liver and renal function defined as a bilirubin of \ 3.0g/dl, and a creatinine of \< 1.5 mg/dl, respectively. 5. absolute neutrophil count (anc) of ≥1,500/mm3 and a platelet count ≥100,000/mm3. 6. a karnofsky performance status score of ≥60 exclusion criteria: 1. patients without satisfactory oncological control of their primary cancer. 2. radiographic evidence of abdominal, pelvic, or intracranial metastatic disease. 3. chemotherapy and/or radiotherapy must have been completed at least one month prior to entry in the study. patients may not receive concurrent chemotherapy, immunotherapy, radiotherapy, or any investigational drugs while participating in this study. 4. significant active medical disease including, but not limited to: * cardiac disease, including: congestive heart failure or angina pectoris; recent (within 1 year) history of a myocardial infarction; uncontrolled hypertension; arrhythmias. * active infections * uncontrolled diabetes mellitus * chronic renal insufficiency * hiv/aids - routine hiv testing will not be performed, but patients known to be hiv positive will be excluded. 5. pregnant or lactating women. 6. allergy to intravenous contrast

Keywords: pleural metastases
a phase ii study of re-treatment of myelofibrosis patients with ruxolitinib/jakavi after treatment interruption due to loss of response and/or adverse event (retreatment trial)

Conditions: Primary Myelofibrosis

Summary: the aim of the study is to assess the efficacy and safety of restarting ruxolitinib after treatment interruption due to loss of response and/or adverse events.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of pmf, ppv mf or pet-mf, irrespective of jak2 mutational status according to the 2008 revised international standard criteria * peripheral blast count \< 10% * requires therapy for mf in the opinion of the investigator * received prior monotherapy treatment with ruxolitinib for at least 12 consecutive weeks and experienced treatment interruption because of lossof response or adverse event * patients adhering to the screening phase assessments and undergoing a a ruxolitinib-free washout period of a minimum of 1 week and a maximum of 8 weeks * ecog performance status 0, 1, 2, or 3 * adequate bone marrow function * written informed consent exclusion criteria: * patients not initially responding (primary resistance) to ruxolitinib therapy * patients who underwent a splenectomy or spleen radiation * patients currently scheduled for bone marrow transplant * patients who have discontinued ruxolitinib \< 14 days prior to screening * patients who are not able to receive a starting dose of ruxolitinib of at least 15 mg total daily dose * leukemic transformation * inadequate renal function * presence of clinically meaningful active bacterial, fungal, parasitic or viral infection which requires therapy * previous history of progressive multifocal leuko-encephalopathy (pml) * clinically significant cardiac disease or significant concurrent medical condition

Keywords: primary myelofibrosis hematologic diseases myeloproliferative disorders inc424 ruxolitinib
evaluation of bortezomib induced peripheral neuropathy of multiple myeloma (mm) patients

Conditions: Multiple Myeloma; Peripheral Neuropathy

Summary: in the present study we are planning to study electrophysiological changes related to the dose and time of bortezomib administration in newly diagnosed patients with mm, during the first months of treatment and 6 months after ending. in addition a possible correlation between the incidence of bipn and the subtype of myeloma and other risk factors will be investigated.


Eligibility criteria:
inclusion criteria: * age\> 18 * patients with multiple myeloma stage ii, iii (durie and salmon staging) prior to bortezomib therapy * eastern cooperative oncology group (ecog) performance status ≤ 2 * be willing and able to comply with the protocol treatment for the duration of the study * patient's written informed consent exclusion criteria: * multiple myeloma on progression * incidence of relapsed or refractory myeloma * patients with the existing neuropathy at the time of the diagnosis

Keywords: multiple myeloma bortezomib peripheral neuropathy evaluation evaluation of electrophysiological changes related to the dose and time of bortezomib administration investigation of correlation between the incidence of bipn and the subtype of myeloma
knowledge, perception, usage and concerns of artificial intelligence applications in periodontology

Conditions: AI (Artificial Intelligence)

Summary: statement of problem: knowledge gap about knowledge, perception ,usage and concerns of artificial intelligence applications in periodontology among periodontists. aim of the study: to investigate ' periodontists' knowledge, perception , usage and concerns towards ai systems' applications in periodontology. materials and methods this will be done by a self-administered, 33-item questionnaire . the questionnaire is divided into five sections.the first section, known as part a, focus on five open-ended questions on sociodemographic characteristics, where participants enter their age, gender, academic affiliation. part b consists of closed-ended questions, identifying the basic knowledge of the periodontists participating in ai using a likert three-point scale (yes / no / maybe) . part c consists of questions assessing the perception of periodontists towards the use of ai using a likert three-point scale (yes / no / maybe). part d consists of questions focusing on the usage of ai applications . part e consists of questions assessing concerns of ai applications in periodontology using a likert three-point scale (yes / no / maybe) . this study will be conducted in accordance with the code of ethics of the research ethics committee at the faculty of dentistry, at ain shams university. this survey aims to assess the knowledge, perception , usage and concerns of ai applications among periodontists. the questionnaire will be distributed to periodontologists in the faculty of dentistry at ain shams university. participants will be voluntary and anonymous. the questionnaire consists of five parts and the average time to complete the questionnaire is 10-12 min


Eligibility criteria:
inclusion criteria: * all participants should be post-graduate periodontists. * periodontists at egypt exclusion criteria: * any undergraduate dental student
safety and efficacy study of sotagliflozin on glucose control in participants with type 2 diabetes, moderate impairment of kidney function, and inadequate blood sugar control

Conditions: Type 2 Diabetes Mellitus; Chronic Kidney Disease Stage 3

Summary: primary objective: to demonstrate the superiority of sotagliflozin 200 milligrams (mg) and sotagliflozin 400 mg versus placebo on hba1c reduction at 26 weeks in participants with type 2 diabetes who have inadequate glycemic control and moderate renal impairment. secondary objectives: * to assess the effects of sotagliflozin 200 mg and 400 mg versus placebo with respect to additional measures of glycemic control, blood pressure, and body weight. * to evaluate the safety of sotagliflozin 200 mg and 400 mg versus placebo.

the study duration is up to 60 weeks including 4 weeks prior to randomization, 52 weeks of randomized treatment, and a visit 4 weeks after completion of the randomized treatment period.

Eligibility criteria:
inclusion criteria : * participants with type 2 diabetes (drug-naïve or on antidiabetic therapy) and documented moderate renal insufficiency defined by an estimated glomerular filtration rate (egfr) (based on the 4 variable modification of diet in renal disease (mdrd) equation) of ≥30 and \<60 milliliter per minute (ml/min)/1.73 meter square (m\^2) (chronic kidney disease \[ckd\] 3a, 3b). * participants has given written informed consent to participate in the study in accordance with local regulations. exclusion criteria: * hemoglobin a1c (hba1c) of \ 11.0%. * type 1 diabetes. * women of childbearing potential (wocbp) not willing to use highly effective method(s) of birth control during the study treatment period and the follow-up period, or who are unwilling or unable to be tested for pregnancy during the study. * treatment with a sodium-glucose cotransporter type 2 (sglt2) inhibitor (canagliflozin, dapagliflozin, empagliflozin) during the last 12 months. * uncontrolled high blood pressure. * participants with severe anemia, severe cardiovascular (including congestive heart failure new york heart association iv), respiratory, hepatic, neurological, psychiatric, or active malignant tumor or other major systemic disease or patients with short life expectancy that, according to the investigator, will preclude their safe participation in this study, or will make implementation of the protocol or interpretation of the study results difficult. * lower extremity complications (such as skin ulcers, infection, osteomyelitis and gangrene) identified during the screening period, and still requiring treatment at randomization. the above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
apatinib plus ie chemotherapy (ifosfamide and etoposide) for relapsed or refractory osteosarcoma

Conditions: Effect of Drug; Toxicity, Drug

Summary: apatinib has led to positive responses in the treatment of osteosarcoma refractory to first-line chemotherapy. however, apatinib demonstrates only short-lived activity, and the disease control of musculoskeletal lesions is worse than that of pulmonary lesions. this treatment failure has been partly overcome by the addition of ifosfamide and etoposide (ie). we have ever retrospectively compared the activity of apatinib + ie in relapsed or refractory osteosarcoma in two sarcoma centers in china and concluded that for osteosarcoma with multiple sites of metastasis, apatinib + ie demonstrated clinically meaningful antitumor activity and delayed disease progression in patients with recurrent or refractory osteosarcoma after failure of chemotherapy. however to overcome the influence of other interventions on the outcome, we are currently performing a prospective trial to investigate this combination, from which more accurate data on this treatment strategy are expected.


Eligibility criteria:
inclusion criteria: * 1) histologically confirmed high-grade osteosarcoma; * 2) initial treatment in the orthopedic/oncology departments of peking university people's hospital or peking university shougang hospital; * 3) progression less than 6 months after first-line chemotherapy with a combination of high-dose methotrexate, doxorubicin, cisplatin and ifosfamide (first-line chemotherapy); * 4) measurable lesions according to the response evaluation criteria for solid tumors (recist 1.1) ; * 5) eastern cooperative oncology group performance status ≤ 2 ; * 6) acceptable haematologic, hepatic, and renal function. exclusion criteria: * those who had been previously treated with antiangiogenic tkis and single ie chemotherapy; * those who had severe or uncontrolled medical disorders that could jeopardize the outcomes of the study. these confounding conditions included, cardiac clinical symptoms or disease with left ventricular ejection fraction\<50%, and hypertension that could not be well controlled with antihypertensive drugs.; * all patients were assessed by the sarcoma board including a thoracic surgeon with at least 10 years surgical experience. patients with lung metastases only were carefully assessed for eligibility for metastasectomy, of whom those who were suitable for surgery were excluded from this study; * weight loss of 20% or more before illness; * brain or leptomeningeal metastasis; * surgical procedure or radiotherapy within 4 weeks of enrollment; * activegastroduodenal ulcer, previous condition associated with risk of bleeding or requiring anticoagulation; * proteinuria or hematuria, denutrition with albuminemia \<25 g/l; * women who were pregnant or breast feeding, other malignancy; * positive hbv/hcv/hiv serology, and known allergy to the experimental agents.

Keywords: osteosarcoma apatinib ifosfamide etoposide advanced
dapagliflozin efficacy and action in nash

Conditions: Nonalcoholic Steatohepatitis

Summary: this is a multicentre, randomized, placebo-controlled trial to assess the efficacy and safety of dapagliflozin on improving non-alcoholic steatohepatitis as determined by liver biopsies and metabolic risk factors.


Eligibility criteria:
inclusion criteria: * men or women aged≥18 years; * non-alcoholic steatohepatitis as determined by liver biopsies within 6 months; * patients with t2dm at screening had to have stable glycaemic control (hba1c \<9.5%) . exclusion criteria: 1. significant alcohol consumption in the past six months (consumed more than 20 g/day for women or 30 g/day for men); 2. a history of alcoholic liver disease, chronic viral hepatitis, drug-induced hepatitis, autoimmune hepatitis, cirrhosis, and liver cancer; 3. obstructive biliary disease; 4. having any medical condition that would affect metabolism (i.e. cushing syndrome, known hyperthyroidism or hypothyroidism); 5. poor glucose control (defined as hba1c≤ 9.5% within 3 months) if diagnosed with t2dm, or taking any antidiabetic medication that would affect metabolism or weight loss (i.e. tzd, glp-1, dpp-4i or initially using insulin in the past 3 months); 6. taking any medication (i.e. cortisol, methotrexate)that would affect steatohepatitis for more than two weeks in the past year; 7. chronic kidney disease or severe impaired renal function (serum creatinine≥ 2.0mg/dl); 8. serum alanine aminotransferase (alt) greater than 300u/l 9. a history of type 1 diabetes; 10. a history of bladder cancer; 11. women who are pregnant or plan to become pregnant; 12. serious medical disease with likely life expectancy less than 5 years; 13. patients who cannot be followed for 24 months (due to a health situation or migration); 14. participation in other clinical trial in the 30 days before randomization; 15. patients who are unwilling or unable to give informed consent.

Keywords: nonalcoholic steatohepatitis sglt-2 inhibitor
temporary clamping of drains combined with tranexamic acid reduce blood loss after tka: a prospective rct

Conditions: Osteoarthritis of Knee

Summary: total knee arthroplasty (tka) may be associated with significant blood loss, and transfusion carries substantial risk of immunologic reaction and disease transmission. several methods reportedly reduce postoperative blood loss and avoid homologous blood transfusion with traditional tka approaches. drain clamping was one of the widely used method and tranexamic acid administration was the recently adjuvant method to reduce blood loss in tka. however, there were several regimens in either drain clamping or tranexamic acid administration reported in previous studies. our objective was to compare the efficacy of our drain clamping protocol and/or tranexamic acid regimen for reducing blood loss and transfusion in tka.


Eligibility criteria:
inclusion criteria: * the patients younger than 85 years with knee osteoarthritis exclusion criteria: * the patient diagnosed secondary osteoarthritis (eg, rheumatoid arthritis, posttraumatic arthritis, gouty arthritis, postseptic arthritis) * high-risk medical comorbid patient * the patient who was planed for simultaneous bilateral tkas * the patient who had history of thromboembolic disease or bleeding disorder * the patient who was receiving anticoagulant drug treatment * the patient who had allergy to tranexamic acid
assessment of variations of the number of roots &amp; root canal configurations of maxillary premolars and their relation to the floor of the maxillary sinus

Conditions: Root Canal Configurations of Permanent Maxillary Premolars

Summary: assessment of variations of the number of roots \& root canal configurations of permanent maxillary premolars and their relation to the floor of the maxillary sinus

assessment of variations of the number of roots \& root canal configurations of permanent maxillary premolars and their relation to the floor of the maxillary sinus in a sample of egyptian population using cbct: an observational cross-sectional study

Eligibility criteria:
inclusion criteria: * fully maturated and erupted maxillary permanent premolars of egyptian patients, males or females. * intact maxillary premolars' roots without fractures or cracks. * maxillary premolars without posts or previous root canal treatment. * cbct scans of different fields of view could be included as long as it shows maxillary premolars. * cbct scans of 0.2 mm voxel resolution {the maximum voxel size accepted for endodontic imaging} exclusion criteria: * maxillary premolars with: developmental anomalies. external or internal root resorption. root canal calcification. previous root canal treatment post restorations. root caries especially reaching the bifurcation area. * evidence of apicectomy or periapical surgery * cbct images of poor quality or artifacts interfering with the assessment of the root canals.
a study of autonomic dynamic dysfunction to predict infections after spinal cord injury.

Conditions: Trauma, Spinal Cord; SPINAL Fracture

Summary: the study is designed to investigate whether autonomic shifts (dysautonomia, sympatho-vagal instability) that develop after sci have value in predicting sci-associated infections (sci-ai). sci-ai impair outcomes by (1) reducing the intrinsic neurological recovery potential and (2) increasing mortality. heart rate variability (hrv) data will be tracked in both the time and frequency domains to discriminate between the relative contribution of sympathetic and parasympathetic innervation to changes in hrv. the ability to predict infections will enable novel treatments thereby reducing infection-associated mortality and improving neurological and functional outcomes.


Eligibility criteria:
inclusion criteria: 1. patients with acute isolated spinal cord injury (ais a-d) planned for surgical stabilization and decompression, lesion may include more than 1 segment 2. patients with acute isolated spinal fracture, lesion may include more than 1 segment 3. legal age of the patient 4. documented informed consent of the patient exclusion criteria: 1. non-traumatic spinal cord injury 2. concomitant traumatic brain injury (tbi) (definition: i) patient with severe tbi (glasgow coma scale ≤ 8) and ii) patients with intracranial pressure monitoring sensors) 3. neoplasia and/or antineoplastic therapy 4. pregnancy, lactation
researches of retinal artery lesions and acute coronary syndrome

Conditions: Acute Coronary Syndrome

Summary: this study is to investigate the relationship between staging of retinal artery lesions and the prognosis of acute coronary syndrome (acs) in a chinese population. all the patients were divided into four groups according retinal artery lesions.the endpoints were main adverse cardiovascular and cerebrovascular events (macce), including all-cause death, myocardial infarction (mi), and stroke after 3 to 6 years of follow-up.

the aim of this study was to determine whether retinal artery lesions can predict long-term adverse outcomes in acute coronary syndrome (acs) patients after drug-eluting stent (des) implant. a total of 660 consecutive patients with acs who underwent coronary angiography and percutaneous coronary intervention enrolled this study at the beijing mentougou district hospital, beijing tiantan hospital and beijing shijitan hospital. all the subjects were divided into two groups based on the retinal artery lesions: group 1, retinal artery lesions≤ stage 2 (n=296) and group 2 (n=364), retinal artery lesions \> stage 2. beside,the eye fundus examination was done in all patients to mesure the extent and severity of atherosclerotic vascular lesions in the retinal arteries . patients were excluded from the study if they had severe nephropathy (gfr\< 30 ml/min/1.73 m2), vascular obstruction, acute illnesses or any other condition that was thought to contraindicated coronary angiography. primary endpoint was all-cause mortality. the composite endpoint was defined as major adverse cardiac and cerebrovascular events (macce), namely recurrent serious angina pectoris, nonfatal mi, revascularization and stroke.

Eligibility criteria:
inclusion criteria: * consecutive patients with acs who performed coronary angiography (cag) and percutaneous coronary intervention (pci). exclusion criteria: * patients were excluded from the study if they had heart failure, malignancies, renal insufficiency (creatinine \> 133µmol/l), liver disease, stroke and severe lung disease.

Keywords: relationship retinal artery lesions long-term outcomes